Melanoma Treatment - New Investigational Drug Shows Promise in Early Phase I Clinical Trials
Novel compound dubbed MK-8353 offers hope in the treatment of melanoma and other cancers with mutations in BRAF or RAS genes in early phase I clinical trials
Novel compound dubbed MK-8353 offers hope in the treatment of melanoma and other cancers with mutations in BRAF or RAS genes in early phase I clinical trials
No comments:
Post a Comment